Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Drug–Drug and Drug–Natural Compound Interactions: From Bench to Bedside
share announcement

Drug–Drug and Drug–Natural Compound Interactions: From Bench to Bedside

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".

Deadline for manuscript submissions: closed (21 April 2023) | Viewed by 2152

Special Issue Editors

Dr. Shian-Ren Lin

E-Mail Website
Guest Editor
FullHope Biomedical Co. Ltd., New Taipei City, 241405, Taiwan
Interests: drug/drug interaction; metabolic syndrome; natural compounds
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ju-Seop Kang

E-Mail Website
Guest Editor
Department of Pharmacology & Clinical Pharmacology Laboratory, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea
Interests: clinical trials; new drug development; drug/drug(food) interaction; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Paola Nieri

E-Mail Website
Guest Editor
Department of Pharmacy, Università di Pisa, 56126 Pisa, Italy
Interests: microRNA; anticancer drugs; circulating biomarkers; marine compounds; natural compounds; melanoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

To reduce the adverse effect and enhance the treatment efficacy, a series of drug combination is frequently applied for treatment of metabolic syndrome and cancers. Moreover, patients with metabolic syndrome or cancers usually take herbal supplements for remission of symptoms. Several studies observed that combination of the chemotherapeutic drugs or drug/natural compounds has additional therapeutic efficacies than drug or natural compounds alone. However, several studies also demonstrated that patients receiving drug/drug combination or drug/natural compounds combination experience unexpected adverse effects whereas which underlying mechanism is still elusive. This Special Issue intends to collect any studies, including research articles for evaluating new synergistic combination and their synergistic mechanisms, systemic reviews for evaluating potential drug/drug toxicity, or clinical trials for assessing the putative populations experiencing drug/drug synergism or toxicities.

Dr. Shian-Ren Lin
Prof. Dr. Ju-Seop Kang
Prof. Dr. Paola Nieri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • synergism
  • drug interaction

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 559 KiB  
Article
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
by Teodor Salmen, Florin-Teodor Bobirca, Ioana-Cristina Bica, Doina-Andrada Mihai, Corina Pop and Anca Pantea Stoian
Life 2023, 13(3), 839; https://doi.org/10.3390/life13030839 - 20 Mar 2023
Cited by 2 | Viewed by 1748
Abstract
Aim: We evaluated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose-lowering drugs and drugs for the treatment of type 2 diabetes mellitus (T2DM), in a standard-of-care regimen with maximum tolerated [...] Read more.
Aim: We evaluated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose-lowering drugs and drugs for the treatment of type 2 diabetes mellitus (T2DM), in a standard-of-care regimen with maximum tolerated doses, and, respectively, when compared with metformin. Methods: We conducted a retrospective, observational study on 405 patients that were seen in the outpatient clinic of the N Paulescu National Institute for Diabetes Mellitus, Bucharest, Romania, in 2019. Their demographics, metabolic parameters, and medication safety were evaluated at three follow-up visits, from baseline, six months, and twelve months. Results: Both SGLT-2is and GLP-1 RAs are safe regarding creatinine, eGFR, urea, GOT, and GPT upon the comparison of the data from the six- and twelve-month visits with the initial visit, and also the twelve-month visit with the six-month visit. Moreover, when comparing SGLT-2is and GLP-1 RAs with metformin, there are safety data only for urea. Conclusions: In this retrospective analysis, both SGLT-2is and GLP-1 RAs, when used in conjunction with other glucose-lowering, blood-pressure-lowering, and lipid-lowering medications, appeared to be safe for the management of T2DM. Full article
(This article belongs to the Special Issue Drug–Drug and Drug–Natural Compound Interactions: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop